Lineage Cell Therapeutics (LCTX) Gains from Investment Securities (2010 - 2026)
Lineage Cell Therapeutics posted quarterly Gains from Investment Securities of $40000.0 for Q1 2026, up 166.67% year-on-year from $15000.0 in Q1 2025, and up 3900.0% on a QoQ basis from $1000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) has 17 years of Gains from Investment Securities data on file, last reported at $40000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 166.67% year-over-year to $40000.0; the trailing twelve-month figure through Mar 2026 stood at $39.3 million (up 103421.05% YoY), and the FY2025 full-year result was $23.2 million, up 130.25% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $40000.0, up from $1000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $26.6 million in Q3 2025 and bottomed at $1000.0 in Q4 2023.
- The 5-year median for Gains from Investment Securities is $795000.0 (2022), against an average of $6.2 million.
- The widest annual swing landed in 2022, when Gains from Investment Securities jumped 20793.1%; it then sank 99.98% in 2023.
- A 5-year view of Gains from Investment Securities shows it stood at $6.0 million in 2022, then tumbled by 99.98% to $1000.0 in 2023, then jumped by 1008800.0% to $10.1 million in 2024, then sank by 99.99% to $1000.0 in 2025, then jumped by 3900.0% to $40000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $40000.0 (Q1 2026), $1000.0 (Q4 2025), and $26.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Lineage Cell Therapeutics | 325.89 Mn | 261.99 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40,000.00 |
| Mar 31, 2026 | 40,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 26.56 Mn |
| Sep 30, 2025 | 26.56 Mn |
| Jun 30, 2025 | 12.74 Mn |
| Jun 30, 2025 | 12.74 Mn |
| Mar 31, 2025 | 15,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Jun 30, 2024 | 10.09 Mn |
| Jun 30, 2024 | 10.09 Mn |
| Mar 31, 2024 | 23,000.00 |
| Mar 31, 2024 | 23,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 25.44 Mn |
| Sep 30, 2023 | 25.44 Mn |
| Jun 30, 2023 | 6.27 Mn |
| Jun 30, 2023 | 6.27 Mn |
| Mar 31, 2023 | 13,000.00 |
| Mar 31, 2023 | 13,000.00 |
| Dec 31, 2022 | 6.00 Mn |
| Dec 31, 2022 | 6.00 Mn |
| Sep 30, 2022 | 241,000.00 |
| Sep 30, 2022 | 241,000.00 |
| Jun 30, 2022 | 795,000.00 |
| Jun 30, 2022 | 795,000.00 |
| Mar 31, 2022 | 5.30 Mn |
| Mar 31, 2022 | 5.30 Mn |
| Dec 31, 2021 | -29,000.00 |
| Dec 31, 2021 | -29,000.00 |
| Sep 30, 2021 | 350,000.00 |
| Sep 30, 2021 | 350,000.00 |
| Jun 30, 2021 | 5.12 Mn |
| Jun 30, 2021 | 5.12 Mn |
| Mar 31, 2021 | 5.19 Mn |
| Mar 31, 2021 | 5.19 Mn |
| Dec 31, 2020 | -134,000.00 |
| Dec 31, 2020 | -134,000.00 |
| Sep 30, 2020 | 350,000.00 |
| Sep 30, 2020 | 350,000.00 |
| Jun 30, 2020 | 350,000.00 |
| Jun 30, 2020 | 350,000.00 |
| Mar 31, 2020 | 350,000.00 |
| Mar 31, 2020 | 350,000.00 |
| Dec 31, 2019 | 350,000.00 |
| Dec 31, 2019 | 350,000.00 |
| Sep 30, 2019 | 490,000.00 |
| Sep 30, 2019 | 490,000.00 |
| Jun 30, 2019 | 16.00 Mn |
| Jun 30, 2019 | 16.00 Mn |
| Mar 31, 2019 | 495,000.00 |
| Mar 31, 2019 | 495,000.00 |
| Dec 31, 2018 | -3.11 Mn |
| Dec 31, 2018 | -3.11 Mn |
| Sep 30, 2018 | 16.00 Mn |
| Sep 30, 2018 | 16.00 Mn |
| Jun 30, 2018 | 1.24 Mn |
| Jun 30, 2018 | 1.24 Mn |
| Mar 31, 2018 | 1,239.00 |
| Mar 31, 2018 | 1,239.00 |
| Dec 31, 2017 | -1.60 Mn |
| Dec 31, 2017 | -1.60 Mn |
| Sep 30, 2017 | 606,000.00 |
| Sep 30, 2017 | 606,000.00 |
| Jun 30, 2017 | 1.51 Mn |
| Jun 30, 2017 | 1.51 Mn |
| Mar 31, 2017 | -3,000.00 |
| Mar 31, 2017 | -3,000.00 |
| Dec 31, 2016 | 626,000.00 |
| Dec 31, 2016 | 626,000.00 |
| Sep 30, 2016 | -62,000.00 |
| Sep 30, 2016 | -62,000.00 |
| Jun 30, 2016 | 174,000.00 |
| Jun 30, 2016 | 174,000.00 |
| Mar 31, 2016 | -112,000.00 |
| Mar 31, 2016 | -112,000.00 |
| Dec 31, 2015 | 400,000.00 |
| Dec 31, 2015 | 400,000.00 |
| Sep 30, 2015 | 1.10 Mn |
| Sep 30, 2015 | 1.10 Mn |
| Jun 30, 2015 | 550,000.00 |
| Jun 30, 2015 | 550,000.00 |
| Mar 31, 2015 | 440,000.00 |
| Mar 31, 2015 | 440,000.00 |
| Dec 31, 2014 | -9,000.00 |
| Dec 31, 2014 | -9,000.00 |
| Sep 30, 2014 | 1.41 Mn |
| Sep 30, 2014 | 1.41 Mn |
| Jun 30, 2014 | 1.21 Mn |
| Jun 30, 2014 | 1.21 Mn |
| Mar 31, 2014 | 1.21 Mn |
| Mar 31, 2014 | 1.21 Mn |
| Dec 31, 2013 | 15,000.00 |
| Dec 31, 2013 | 15,000.00 |
| Sep 30, 2013 | 1.58 Mn |
| Sep 30, 2013 | 1.58 Mn |
| Jun 30, 2013 | 1.16 Mn |
| Jun 30, 2013 | 1.16 Mn |
| Mar 31, 2013 | 77,280.00 |
| Mar 31, 2013 | 77,280.00 |
| Sep 30, 2012 | 280,000.00 |
| Sep 30, 2012 | 280,000.00 |
| Jun 30, 2012 | -3,546.00 |
| Jun 30, 2012 | -3,546.00 |
| Mar 31, 2012 | 105,000.00 |
| Mar 31, 2012 | 105,000.00 |
| Dec 31, 2011 | 6,502.00 |
| Dec 31, 2011 | 6,502.00 |
| Sep 30, 2011 | 11,876.00 |
| Sep 30, 2011 | 11,876.00 |
| Jun 30, 2011 | 96,593.00 |
| Jun 30, 2011 | 96,593.00 |
| Dec 31, 2010 | 3.32 Mn |
| Dec 31, 2010 | 3.32 Mn |